GMAB
Genmab AS
35.40$
+0.1%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +33.2% | +60.3% | +30.2% | +27.9% | +77.4% | +88.4% | -16.8% | +72.3% | +13.6% | +30.7% | -82.7% | |
| – | – | – | – | – | – | – | – | – | – | +335.8% | -68.6% | |
| – | +33.2% | +60.3% | +30.2% | +27.9% | +77.4% | +88.4% | -16.8% | +72.3% | +12.0% | +26.4% | -83.4% | |
| – | -3.6% | +35.5% | +32.3% | +63.7% | +66.7% | +31.5% | +33.3% | +33.0% | +37.2% | +27.8% | -84.0% | |
| – | +14.7% | +12.3% | +43.5% | +45.4% | +60.0% | +93.3% | +94.1% | +108.6% | +23.2% | +15.0% | -83.5% | |
| – | -31.2% | +89.6% | +33.8% | +61.1% | +65.9% | +39.2% | +43.9% | +50.8% | +32.6% | +26.6% | -84.4% | |
| – | +175.4% | +44.1% | +27.7% | +2.7% | +91.1% | +139.3% | -53.2% | +112.2% | -15.1% | +26.0% | -81.3% | |
| – | -97.1% | +80.5% | +839.0% | -79.1% | +1,578.7% | +42.9% | +30.0% | +61.5% | +28.6% | +344.4% | -49.1% | |
| – | +154.8% | +49.2% | -5.9% | +51.5% | +77.4% | +106.5% | -33.6% | +77.3% | -18.8% | +62.6% | -86.9% | |
| – | – | – | – | – | +395.6% | +65.4% | -16.1% | +55.4% | -13.9% | +2.7% | -81.7% | |
| – | +153.4% | +55.5% | -7.0% | +33.4% | +47.1% | +119.7% | -37.9% | +84.4% | -20.2% | +80.2% | -87.7% | |
| – | +151.6% | +48.4% | +27.0% | +14.2% | +76.8% | +105.0% | -32.1% | +75.7% | -19.0% | +63.1% | -86.2% |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.